Removing Barriers to Colorectal Cancer Screening Act of 2020

Bill: 116-hr-1570
Sponsor: full_name: Rep. Payne, Donald M., Jr. [D-NJ-10]
Introduced: 2019-03-06
Policy area: Health
Subjects: Cancer

Digestive and metabolic diseases

Medical tests and diagnostic methods

Medicare
Latest action: action_date: 2020-12-10
text: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2019-03-06
action_desc: Introduced in House
text: <p><b>Removing Barriers to Colorectal Cancer Screening Act of </b><b>2019</b></p> <p>This bill waives Medicare&nbsp;coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure.</p>

action_date: 2020-12-09
action_desc: Passed House
text: <p><b>Removing Barriers to Colorectal Cancer Screening Act of </b><b>2020</b></p> <p>This bill modifies cost-sharing requirements for colorectal cancer screening tests, and drug manufacturer reporting requirements, under Medicare medical services.</p> <p>Specifically, the bill waives coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure. The bill phases in implementation over an eight-year period.</p> <p>Additionally, manufacturers of covered drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.</p>

tv_txt: I 116th CONGRESS 1st Session H. R. 1570 IN THE HOUSE OF REPRESENTATIVES March 6, 2019 Mr. Payne (for himself, Mr. Rodney Davis of Illinois , Mr. McEachin , Mr. McKinley , Ms. Barragán , Mr. Bishop of Georgia , Mr. Brendan F. Boyle of Pennsylvania , Ms. Brownley of California , Mr. Cicilline , Mr. Courtney , Mr. DeFazio , Ms. DeLauro , Mr. Deutch , Mrs. Dingell , Mr. Engel , Mr. Evans , Mr. Foster , Ms. Gabbard , Mr. Gallego , Mr. Garamendi , Mr. Grijalva , Mr. Hastings , Mr. Heck , Mr. Higgins of New York , Ms. Hill of California , Ms. Kelly of Illinois , Mr. Khanna , Mr. Kilmer , Mr. Krishnamoorthi , Ms. Lee of California , Mr. Lipinski , Mr. Sean Patrick Maloney of New York , Ms. Matsui , Ms. McCollum , Ms. Moore , Mr. Moulton , Ms. Norton , Mr. O'Halleran , Mr. Panetta , Mr. Quigley , Miss Rice of New York , Mr. Ruppersberger , Ms. Speier , Ms. Wasserman Schultz , Mrs. Watson Coleman , Mr. Van Drew , Mr. Babin , Mr. Collins of New York , Mr. Cook , Mr. Fitzpatrick , Mr. Gianforte , Ms. Herrera Beutler , Mr. Hice of Georgia , Mr. Hunter , Mr. Joyce of Ohio , Mr. Kelly of Mississippi , Mr. King of Iowa , Mr. Loudermilk , Mr. Mooney of West Virginia , Mr. Mullin , Mr. Perry , Mr. Shimkus , Ms. Stefanik , Mr. Tipton , Mr. Turner , Mr. Zeldin , Ms. DelBene , Ms. Clarke of New York , Mr. Gibbs , Miss González-Colón of Puerto Rico , Mr. Bera , Mr. Smith of Washington , Mr. Brindisi , Ms. Fudge , Mr. Sires , Mr. Nadler , Mr. Takano , Ms. Velázquez , Mrs. Axne , Mr. David Scott of Georgia , Ms. Schakowsky , Mr. Tonko , Mr. Larson of Connecticut , Mr. Michael F. Doyle of Pennsylvania , Mr. Price of North Carolina , Mr. Cisneros , Mr. Yarmuth , Mr. Keating , Mr. Lynch , Mr. Sherman , Ms. Johnson of Texas , Mr. Larsen of Washington , Mr. Schiff , Ms. Roybal-Allard , Mr. McNerney , Mr. Kustoff of Tennessee , Mr. Butterfield , Mr. Espaillat , Mrs. Beatty , Mr. Suozzi , Mr. Scott of Virginia , Mr. Pascrell , Ms. Adams , Mrs. Davis of California , Mr. Morelle , Ms. Frankel , Mr. Jeffries , Mr. Clyburn , Ms. Waters , Mr. Johnson of Georgia , Ms. Pressley , Mr. Danny K. Davis of Illinois , Mr. Clay , Mr. Rush , Mr. Carson of Indiana , Mr. Meeks , Mr. Veasey , Mr. Richmond , Ms. Bass , Mr. Brown of Maryland , and Mr. Green of Texas ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to waive coinsurance under Medicare for colorectal cancer screening tests, regardless of whether therapeutic intervention is required during the screening.

1. Short title This Act may be cited as the Removing Barriers to Colorectal Cancer Screening Act of 2019 . 2. Findings Congress finds the following: (1) Colorectal cancer is the second leading cause of cancer death among men and women combined in the United States. (2) In 2019, more than 145,600 Americans will be diagnosed with colorectal cancer and approximately 51,000 Americans will die from it. (3) Approximately 60 percent of colorectal cancer cases and 70 percent of deaths occur in those aged 65 and older. (4) Colorectal cancer screening colonoscopy allows for the detection and removal of polyps, or abnormal growths, that could become cancerous, as well as for the early detection of colorectal cancer when treatment can be most effective. (5) Although colorectal cancer is largely preventable, one in three adults over 50 years of age are not up to date with recommended colorectal cancer screening. (6) Over 1,700 organizations have committed to eliminating colorectal cancer as a major public health problem and are working toward the shared goal of reaching 80 percent screened for colorectal cancer in every community. (7) Colorectal cancer screening colonoscopy is a highly effective preventive service, and removing financial barriers can help to increase screening rates. 3. Waiving Medicare coinsurance for colorectal cancer screening tests (a) In general Section 1833(a)(1)(Y) of the Social Security Act ( 42 U.S.C. 1395l(a)(1)(Y) ) is amended by inserting , including a colorectal cancer screening test (regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test), after section 1861(ddd)(3) . (b) Effective date The amendment made by this section shall apply to items and services furnished after the date of the enactment of this Act.

tv_txt: I 116th CONGRESS 2d Session H. R. 1570 IN THE HOUSE OF REPRESENTATIVES AN ACT To amend title XVIII of the Social Security Act to waive coinsurance under Medicare for colorectal cancer screening tests, regardless of whether therapeutic intervention is required during the screening, and for other purposes.

1. Short title This Act may be cited as the Removing Barriers to Colorectal Cancer Screening Act of 2020 . 2. Waiving medicare coinsurance for certain colorectal cancer screening tests (a) In general Section 1833(a) of the Social Security Act ( 42 U.S.C. 1395l(a) ) is amended— (1) in the second sentence, by striking section 1834(0) and inserting section 1834(o) ; (2) by moving such second sentence 2 ems to the left; and (3) by inserting the following third sentence following such second sentence: For services furnished on or after January 1, 2022, paragraph (1)(Y) shall apply with respect to a colorectal cancer screening test regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test. . (b) Special coinsurance rule for certain tests Section 1833 of the Social Security Act ( 42 U.S.C. 1395l ) is amended— (1) in subsection (a)(1)(Y), by inserting subject to subsection (dd), before with respect to ; and (2) by adding at the end the following new subsection: (dd) Special coinsurance rule for certain colorectal cancer screening tests (1) In general In the case of a colorectal cancer screening test to which paragraph (1)(Y) of subsection (a) would not apply but for the third sentence of such subsection that is furnished during a year beginning on or after January 1, 2022, and before January 1, 2030, the amount paid shall be equal to the specified percent (as defined in paragraph (2)) for such year of the lesser of the actual charge for the service or the amount determined under the fee schedule that applies to such test under this part (or, in the case such test is a covered OPD service (as defined in subsection (t)(1)(B)), the amount determined under subsection (t)). (2) Specified percent defined For purposes of paragraph (1), the term specified percent means— (A) for 2022 and 2023, 80 percent; (B) for 2024 and 2025, 85 percent; (C) for 2026 and 2027, 90 percent; and (D) for 2028 and 2029, 95 percent. . (c) Conforming amendments Paragraphs (2) and (3) of section 1834(d) of the Social Security Act ( 42 U.S.C. 1395m(d) ) are each amended— (1) in subparagraph (C)(ii), in the matter preceding subclause (I), by striking Notwithstanding and inserting Subject to section 1833(a)(1)(Y), but notwithstanding ; and (2) in subparagraph (D), by striking If during and inserting Subject to section 1833(a)(1)(Y), if during . 3. Requiring certain manufacturers to report drug pricing information with respect to drugs under the Medicare program (a) In general Section 1847A of the Social Security Act ( 42 U.S.C. 1395w–3a ) is amended— (1) in subsection (b)— (A) in paragraph (2)(A), by inserting or subsection (f)(2), as applicable before the period at the end; (B) in paragraph (3), in the matter preceding subparagraph (A), by inserting or subsection (f)(2), as applicable, before determined by ; and (C) in paragraph (6)(A), in the matter preceding clause (i), by inserting or subsection (f)(2), as applicable, before determined by ; and (2) in subsection (f)— (A) by striking For requirements and inserting the following: (1) In general For requirements ; and (B) by adding at the end the following new paragraph: (2) Manufacturers without a rebate agreement under title XIX (A) In general If the manufacturer of a drug or biological described in subparagraph (C), (E), or (G) of section 1842(o)(1) or in section 1881(b)(14)(B) that is payable under this part has not entered into and does not have in effect a rebate agreement described in subsection (b) of section 1927, for calendar quarters beginning with the second calendar quarter beginning on or after the date of the enactment of this paragraph, such manufacturer shall report to the Secretary the information described in subsection (b)(3)(A)(iii) of such section 1927 with respect to such drug or biological in a time and manner specified by the Secretary. For purposes of applying this paragraph, a drug or biological described in the previous sentence includes items, services, supplies, and products that are payable under this part as a drug or biological. (B) Audit Information reported under subparagraph (A) is subject to audit by the Inspector General of the Department of Health and Human Services. (C) Verification The Secretary may survey wholesalers and manufacturers that directly distribute drugs described in subparagraph (A), when necessary, to verify manufacturer prices and manufacturer’s average sales prices (including wholesale acquisition cost) if required to make payment reported under subparagraph (A). The Secretary may impose a civil monetary penalty in an amount not to exceed $100,000 on a wholesaler, manufacturer, or direct seller, if the wholesaler, manufacturer, or direct seller of such a drug refuses a request for information about charges or prices by the Secretary in connection with a survey under this subparagraph or knowingly provides false information. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subparagraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a). (D) Confidentiality Notwithstanding any other provision of law, information disclosed by manufacturers or wholesalers under this paragraph (other than the wholesale acquisition cost for purposes of carrying out this section) is confidential and shall not be disclosed by the Secretary in a form which discloses the identity of a specific manufacturer or wholesaler or prices charged for drugs by such manufacturer or wholesaler, except— (i) as the Secretary determines to be necessary to carry out this section (including the determination and implementation of the payment amount), or to carry out section 1847B; (ii) to permit the Comptroller General of the United States to review the information provided; and (iii) to permit the Director of the Congressional Budget Office to review the information provided. . (b) Enforcement Section 1847A of such Act ( 42 U.S.C. 1395w–3a ) is further amended— (1) in subsection (d)(4)— (A) in subparagraph (A), by striking In general and inserting Misrepresentation ; (B) in subparagraph (B), by striking subparagraph (B) and inserting subparagraph (A), (B), or (C) ; (C) by redesignating subparagraph (B) as subparagraph (D); and (D) by inserting after subparagraph (A) the following new subparagraphs: (B) Failure to provide timely information If the Secretary determines that a manufacturer described in subsection (f)(2) has failed to report on information described in section 1927(b)(3)(A)(iii) with respect to a drug or biological in accordance with such subsection, the Secretary shall apply a civil money penalty in an amount of $10,000 for each day the manufacturer has failed to report such information and such amount shall be paid to the Treasury. (C) False information Any manufacturer required to submit information under subsection (f)(2) that knowingly provides false information is subject to a civil money penalty in an amount not to exceed $100,000 for each item of false information. Such civil money penalties are in addition to other penalties as may be prescribed by law. ; and (2) in subsection (c)(6)(A), by striking the period at the end and inserting , except that, for purposes of subsection (f)(2), the Secretary may, if the Secretary determines appropriate, exclude repackagers of a drug or biological from such term. . (c) Manufacturers with a rebate agreement (1) In general Section 1927(b)(3)(A) of the Social Security Act ( 42 U.S.C. 1396r-8(b)(3)(A) ) is amended by adding at the end the following new sentence: For purposes of applying clause (iii), a drug or biological described in the flush matter following such clause includes items, services, supplies, and products that are payable under this part as a drug or biological. . (2) Technical amendment Section 1927(b)(3)(A)(iii) of the Social Security Act ( 42 U.S.C. 1396r-8(b)(3)(A)(iii) ) is amended by striking section 1881(b)(13)(A)(ii) and inserting section 1881(b)(14)(B) . (d) Report Not later than January 1, 2023, the Inspector General of the Department of Health and Human Services shall assess and submit to Congress a report on the accuracy of average sales price information submitted by manufacturers under section 1847A of the Social Security Act ( 42 U.S.C. 1395w–3a ). Such report shall include any recommendations on how to improve the accuracy of such information. 4. Determination of budgetary effects The budgetary effects of this Act, for the purpose of complying with the Statutory Pay-As-You-Go Act of 2010, shall be determined by reference to the latest statement titled “Budgetary Effects of PAYGO Legislation” for this Act, submitted for printing in the Congressional Record by the Chairman of the House Budget Committee, provided that such statement has been submitted prior to the vote on passage.

Passed the House of Representatives December 9, 2020. Cheryl L. Johnson, Clerk.

tv_txt: IIB 116th CONGRESS 2d Session H. R. 1570 IN THE SENATE OF THE UNITED STATES December 10, 2020 Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions AN ACT To amend title XVIII of the Social Security Act to waive coinsurance under Medicare for colorectal cancer screening tests, regardless of whether therapeutic intervention is required during the screening, and for other purposes.

1. Short title This Act may be cited as the Removing Barriers to Colorectal Cancer Screening Act of 2020 . 2. Waiving medicare coinsurance for certain colorectal cancer screening tests (a) In general Section 1833(a) of the Social Security Act ( 42 U.S.C. 1395l(a) ) is amended— (1) in the second sentence, by striking section 1834(0) and inserting section 1834(o) ; (2) by moving such second sentence 2 ems to the left; and (3) by inserting the following third sentence following such second sentence: For services furnished on or after January 1, 2022, paragraph (1)(Y) shall apply with respect to a colorectal cancer screening test regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test. . (b) Special coinsurance rule for certain tests Section 1833 of the Social Security Act ( 42 U.S.C. 1395l ) is amended— (1) in subsection (a)(1)(Y), by inserting subject to subsection (dd), before with respect to ; and (2) by adding at the end the following new subsection: (dd) Special coinsurance rule for certain colorectal cancer screening tests (1) In general In the case of a colorectal cancer screening test to which paragraph (1)(Y) of subsection (a) would not apply but for the third sentence of such subsection that is furnished during a year beginning on or after January 1, 2022, and before January 1, 2030, the amount paid shall be equal to the specified percent (as defined in paragraph (2)) for such year of the lesser of the actual charge for the service or the amount determined under the fee schedule that applies to such test under this part (or, in the case such test is a covered OPD service (as defined in subsection (t)(1)(B)), the amount determined under subsection (t)). (2) Specified percent defined For purposes of paragraph (1), the term specified percent means— (A) for 2022 and 2023, 80 percent; (B) for 2024 and 2025, 85 percent; (C) for 2026 and 2027, 90 percent; and (D) for 2028 and 2029, 95 percent. . (c) Conforming amendments Paragraphs (2) and (3) of section 1834(d) of the Social Security Act ( 42 U.S.C. 1395m(d) ) are each amended— (1) in subparagraph (C)(ii), in the matter preceding subclause (I), by striking Notwithstanding and inserting Subject to section 1833(a)(1)(Y), but notwithstanding ; and (2) in subparagraph (D), by striking If during and inserting Subject to section 1833(a)(1)(Y), if during . 3. Requiring certain manufacturers to report drug pricing information with respect to drugs under the Medicare program (a) In general Section 1847A of the Social Security Act ( 42 U.S.C. 1395w–3a ) is amended— (1) in subsection (b)— (A) in paragraph (2)(A), by inserting or subsection (f)(2), as applicable before the period at the end; (B) in paragraph (3), in the matter preceding subparagraph (A), by inserting or subsection (f)(2), as applicable, before determined by ; and (C) in paragraph (6)(A), in the matter preceding clause (i), by inserting or subsection (f)(2), as applicable, before determined by ; and (2) in subsection (f)— (A) by striking For requirements and inserting the following: (1) In general For requirements ; and (B) by adding at the end the following new paragraph: (2) Manufacturers without a rebate agreement under title XIX (A) In general If the manufacturer of a drug or biological described in subparagraph (C), (E), or (G) of section 1842(o)(1) or in section 1881(b)(14)(B) that is payable under this part has not entered into and does not have in effect a rebate agreement described in subsection (b) of section 1927, for calendar quarters beginning with the second calendar quarter beginning on or after the date of the enactment of this paragraph, such manufacturer shall report to the Secretary the information described in subsection (b)(3)(A)(iii) of such section 1927 with respect to such drug or biological in a time and manner specified by the Secretary. For purposes of applying this paragraph, a drug or biological described in the previous sentence includes items, services, supplies, and products that are payable under this part as a drug or biological. (B) Audit Information reported under subparagraph (A) is subject to audit by the Inspector General of the Department of Health and Human Services. (C) Verification The Secretary may survey wholesalers and manufacturers that directly distribute drugs described in subparagraph (A), when necessary, to verify manufacturer prices and manufacturer’s average sales prices (including wholesale acquisition cost) if required to make payment reported under subparagraph (A). The Secretary may impose a civil monetary penalty in an amount not to exceed $100,000 on a wholesaler, manufacturer, or direct seller, if the wholesaler, manufacturer, or direct seller of such a drug refuses a request for information about charges or prices by the Secretary in connection with a survey under this subparagraph or knowingly provides false information. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subparagraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a). (D) Confidentiality Notwithstanding any other provision of law, information disclosed by manufacturers or wholesalers under this paragraph (other than the wholesale acquisition cost for purposes of carrying out this section) is confidential and shall not be disclosed by the Secretary in a form which discloses the identity of a specific manufacturer or wholesaler or prices charged for drugs by such manufacturer or wholesaler, except— (i) as the Secretary determines to be necessary to carry out this section (including the determination and implementation of the payment amount), or to carry out section 1847B; (ii) to permit the Comptroller General of the United States to review the information provided; and (iii) to permit the Director of the Congressional Budget Office to review the information provided. . (b) Enforcement Section 1847A of such Act ( 42 U.S.C. 1395w–3a ) is further amended— (1) in subsection (d)(4)— (A) in subparagraph (A), by striking In general and inserting Misrepresentation ; (B) in subparagraph (B), by striking subparagraph (B) and inserting subparagraph (A), (B), or (C) ; (C) by redesignating subparagraph (B) as subparagraph (D); and (D) by inserting after subparagraph (A) the following new subparagraphs: (B) Failure to provide timely information If the Secretary determines that a manufacturer described in subsection (f)(2) has failed to report on information described in section 1927(b)(3)(A)(iii) with respect to a drug or biological in accordance with such subsection, the Secretary shall apply a civil money penalty in an amount of $10,000 for each day the manufacturer has failed to report such information and such amount shall be paid to the Treasury. (C) False information Any manufacturer required to submit information under subsection (f)(2) that knowingly provides false information is subject to a civil money penalty in an amount not to exceed $100,000 for each item of false information. Such civil money penalties are in addition to other penalties as may be prescribed by law. ; and (2) in subsection (c)(6)(A), by striking the period at the end and inserting , except that, for purposes of subsection (f)(2), the Secretary may, if the Secretary determines appropriate, exclude repackagers of a drug or biological from such term. . (c) Manufacturers with a rebate agreement (1) In general Section 1927(b)(3)(A) of the Social Security Act ( 42 U.S.C. 1396r-8(b)(3)(A) ) is amended by adding at the end the following new sentence: For purposes of applying clause (iii), a drug or biological described in the flush matter following such clause includes items, services, supplies, and products that are payable under this part as a drug or biological. . (2) Technical amendment Section 1927(b)(3)(A)(iii) of the Social Security Act ( 42 U.S.C. 1396r-8(b)(3)(A)(iii) ) is amended by striking section 1881(b)(13)(A)(ii) and inserting section 1881(b)(14)(B) . (d) Report Not later than January 1, 2023, the Inspector General of the Department of Health and Human Services shall assess and submit to Congress a report on the accuracy of average sales price information submitted by manufacturers under section 1847A of the Social Security Act ( 42 U.S.C. 1395w–3a ). Such report shall include any recommendations on how to improve the accuracy of such information. 4. Determination of budgetary effects The budgetary effects of this Act, for the purpose of complying with the Statutory Pay-As-You-Go Act of 2010, shall be determined by reference to the latest statement titled “Budgetary Effects of PAYGO Legislation” for this Act, submitted for printing in the Congressional Record by the Chairman of the House Budget Committee, provided that such statement has been submitted prior to the vote on passage.

Passed the House of Representatives December 9, 2020. Cheryl L. Johnson, Clerk